Search / Trial NCT06236022

The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus

Launched by TONGJI HOSPITAL · Jan 24, 2024

Trial Information

Current as of October 04, 2024

Recruiting

Keywords

Description

Dilated cardiomyopathy (DCM), defined as left ventricular or biventricular dilation and systolic dysfunction in the absence of either pressure or volume overload or coronary artery disease sufficient to explain the dysfunction, is associated with poor cardiovascular outcome and poor prognosis. Inflammation, activated by viral persistence, was considered as a key trigger factor of cardiac remodeling and thereby the development of DCM. As a risk factor for DCM, Kaposi's sarcoma-associated herpes virus (KSHV) inhibits the type I IFN signaling pathway and thereby aggravates known cardiotropic v...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * 18 to 70 years of age;
  • * Diagnosed as dilated cardiomyopathy. Specifically, (i) left ventricular ejection fraction \<45% (\>2 SD) and/or fractional shortening \<25% (\>2 SD), as ascertained by echocardiography, radionuclide scanning, or cardiac magnetic resonance imaging; (ii) left ventricular end-diastolic diameter \>117% of the predicted value corrected for age and body surface area (Henry's formula), which corresponds to 2 SD of the predicted normal limit +5%; and (iii) In the absence of severe coronary artery disease or valvular disease.
  • * KSHV DNA seropositivity;
  • * Patients are voluntary and signed informed consent.
  • Exclusion Criteria:
  • * Allergic to rapamycin or its derivatives;
  • * The proportion of neutrophils less than 0.5\*10\^9/L or platelet less than 2.5\*10\^10/L;
  • * Pregnant women or plan to;
  • * Participate in any drug clinical trials within 3 months;
  • * Serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients);
  • * Previous history of cancer or tumor, or pathological examination confirmed precancerous lesions;
  • * Patients were not optimally managed.

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Wuhan, Hubei, China

Wuhan, Hubei, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0